|
|
|
| Clinical Efficacy of Clostridium Butyricum Dual Live Bacteria Powder Combined with Double-Sided Blue Light Therapy in the Treatment of Neonatal Hyperbilirubinemia |
| HUO Zhifang, ZHOU Chuan, SONG Huanqing, LI Jingjing, FENG Xiaoxia |
| The Department of Neonatology, the Second Affiliated Hospital of Zhengzhou University,Zhengzhou Henan 450000 |
|
|
|
|
Abstract 【Objective】 To explore the clinical efficacy of Clostridium Butyricum Dual Live Bacteria Powder combined with double-sided blue light therapy in the treatment of neonatal hyperbilirubinemia. 【Methods】 The clinical data of 107 neonates with hyperbilirubinemia admitted to our hospital from February 2020 to February 2023 were retrospectively analyzed. According to different clinical treatment methods, the neonates were divided into the observation group (n=54) and the control group (n=53). Neonates in the control group received routine treatment and double-sided blue light therapy, while those in the observation group received Clostridium Butyricum Dual Live Bacteria Powder treatment on the basis of the control group. The clinical efficacy, laboratory indicators [total bilirubin (TBiL), procalcitonin (PCT), apolipoprotein M (APOM), C-reactive protein (CRP), CD4+, CD8+, CD4+/CD8+, as well as immunoglobulins (IgG, IgA, IgM)], and the incidence of adverse reactions were compared between the two groups. 【Results】 After treatment, the serum TBiL level of neonates in both groups was significantly lower than that before treatment, and the observation group was lower than the control group, with a statistically significant difference (P<0.05). The total effective rate of the observation group was 88.89% (48/54), which was significantly higher than 66.04% (35/53) of the control group, with a statistically significant difference (χ2=8.027, P<0.05). After treatment, the serum CRP, APOM and PCT levels in both groups were lower than those before treatment, and the observation group was lower than the control group, with statistically significant differences (P<0.05). After treatment, IgG, IgA, IgM, CD4+ and CD4+/CD8+ of neonates in both groups were significantly higher than those before treatment, and CD8+ was lower than that before treatment; moreover, IgG, IgA, IgM, CD4+ and CD4+/CD8+ in the observation group were higher than those in the control group, and CD8+ was lower than that in the control group, with statistically significant differences (P<0.05). The incidence of adverse reactions in the observation group was 3.70% (2/54), which was significantly lower than 18.87% (10/53) in the control group, with a statistically significant difference (P<0.05). 【Conclusion】 It is suggested that Clostridium Butyricum Dual Live Bacteria Powder combined with double-sided blue light therapy has a good clinical efficacy in the treatment of neonatal hyperbilirubinemia, which can significantly reduce the serum TBiL level, improve immune function indicators, alleviate inflammatory response, and has high safety.
|
|
Received: 29 October 2025
|
|
|
|
|
|
[1] ITOH S, OKADA H, KOYANO K, et al. Fetal and neonatal bilirubin metabolism[J].Front Pediatr,2023, 10:1002408.
[2] 胡召毛,唐晓磊. 2种蓝光照射治疗新生儿黄疸的临床效果观察[J].海军医学杂志,2022,43(7):704-707.
[3] 秦晓莉,任晨虹. 茵栀黄口服液与双歧杆菌三联活菌散散联用对新生儿黄疸的影响[J].实用临床医药杂志,2020,24(10):126-128.
[4] 中华医学会儿科学分会新生儿学组,《中华儿科杂志》编辑委员会. 新生儿高胆红素血症诊断和治疗专家共识[J].中华儿科杂志,2014,52(10):745-748.
[5] 晁小云. 新生儿高胆红素血症早期预测及筛查方法研究进展[J].实用临床医药杂志,2020,24(15):129-132.
[6] 黄家虎,孙建华. 新生儿高胆红素血症病因的研究进展[J].医学综述,2021,27(4):680-684.
[7] 邓巧妮,王军焕,杨清洋. 蓝光联合支持治疗方案治疗新生儿病理性黄疸的临床疗效观察[J].贵州医药,2022,46(3):409-410.
[8] 王洁洁,王国凯. 茵栀黄口服液联合双歧杆菌四联活菌治疗新生儿黄疸的效果分析[J].中华全科医学,2022,20(7):1158-1161.
[9] 昝倩倩.酪酸梭菌二联活菌散联合蓝光照射治疗新生儿高胆红素血症的疗效观察[J].实用医技杂志,2021,28(4):515-516.
[10] 唐炜,卢红艳,孙勤,等.高胆红素血症新生儿肠道菌群特点及与β-葡萄糖醛酸苷酶活性的相关性[J].中国当代儿科杂志,2021,23(7):677-683.
[11] 王娟,梁宽.酪酸梭菌二联活菌散联合双面蓝光治疗新生儿高胆红素血症的效果及对β2-MG水平的影响[J].临床医学研究与实践,2023,8(8):58-63.
[12] 师淑锋,陈新亚,李晶.酪酸梭菌二联活菌散与间歇蓝光照射联合应用治疗新生儿高胆红素血症疗效分析[J].数理医药学杂志,2022,35(3):409-411.
[13] 王安琪,厉兰,彭贻界,等.酪酸梭菌二联活菌对儿童抗菌药物相关性腹泻的预防作用及肠道菌群的影响[J].临床药物治疗杂志, 2023, 21(3):34-38. |
|
|
|
2026, Vol. 43 
